Ирбис

Quick links to important sections

Ирбис

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ирбис

What is Ирбис? (Identity & Purpose)

Property Description
Active ingredient Irbesartan
Form Oral film-coated tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common purpose Blood pressure lowering/Cardiovascular support
Origin Synthetic chemical entity

What Type of Medicine is Ирбис? (Classification & Active Ingredient)

Ирбис is a prescription medicine containing the active ingredient Irbesartan. Irbesartan belongs to the high-level pharmacological class known as Angiotensin II Receptor Blockers (ARBs), which act on the body’s cardiovascular system. This classification is clinically recognized for providing effective treatment by managing blood vessel function.

Irbesartan is a synthetic compound and a well-established medication. It is commonly used for the long-term management of high blood pressure and is typically administered as an oral, film-coated tablet. This form is specifically designed for convenient, once-daily dosing, making it suitable for chronic therapeutic regimens.


What is Ирбис Made Of? (Composition and Form)

Ирбис is primarily a single-ingredient preparation containing only Irbesartan, distinguishing it as a monotherapy option. This formulation delivers the therapeutic effect centered solely on the ARB action.

While Ирбис is a single component, some versions, such as Irbis-H, are available as combination tablets that pair Irbesartan with a diuretic like Hydrochlorothiazide. The addition of a diuretic to an ARB like Irbesartan is a recognized strategy in hypertension management. This means the medicine is adaptable and can be used in complex treatment protocols.


What Does Ирбис Do? (General Therapeutic Purpose)

The general therapeutic purpose of Ирбис is to lower and stabilize elevated blood pressure. This makes it an essential component of a treatment plan for patients managing hypertension.

The action of Irbesartan helps blood vessels relax and widen, thereby reducing resistance and making it easier for the heart to pump blood. This specific effect is vital for providing long-term cardiovascular support, aiming to ease the chronic strain on the heart and blood vessels caused by high blood pressure.

What side effects are possible with Ирбис?

Possible Side Effects and Safety Information

The safety profile for Irbesartan (Ирбис) is formally defined by regulatory agencies based on incidence observed in clinical trials and post-marketing reports, categorized by frequency and the body systems affected. The terminology for adverse reactions is aligned with official regulatory classifications.

Official Classification of Adverse Reactions

Classification Examples of Reactions
Common (Reported in ge 1/100 to <1/10 patients) Dizziness, Fatigue, Musculoskeletal pain
Common (In Type 2 diabetic nephropathy patients) Hyperkalemia, Orthostatic dizziness, Orthostatic hypotension
Incidence Not Known (Post-marketing, frequency cannot be estimated) Angioedema, Jaundice, Hepatitis, Impaired renal function

The most frequently reported adverse reactions affect the Nervous System (dizziness) and General Disorders (fatigue). The classification of Incidence Not Known includes serious effects such as Angioedema (swelling of the face, lips, and tongue), which is a potentially severe hypersensitivity reaction documented in post-marketing experience.

Serious Safety Warnings and Population Constraints

Regulatory documents mandate specific warnings for Irbesartan, classifying Fetal Toxicity as a serious risk. Use during the second and third trimesters of pregnancy is absolutely contraindicated due to the potential for fetal and neonatal injury, including renal failure.

Patients with renal impairment or diabetic nephropathy are noted to be at increased risk of Acute Renal Failure and Hyperkalemia (elevated potassium levels). The potential for Symptomatic Hypotension is also noted, particularly following the first dose in individuals who are volume-depleted. Additionally, the medicine is contraindicated for use in combination with Aliskiren in patients with diabetes mellitus, as stated in the official safety information.

Overdose and Emergency Response

Ирбис (an irreversible Monoamine Oxidase Inhibitor) overdose can lead to severe, potentially life-threatening toxicity, often presenting as an exaggerated hyperadrenergic or serotonergic crisis. Symptoms can be delayed, sometimes appearing 6 to 24 hours after ingestion, necessitating prolonged medical observation. The severity of the reaction depends on the amount consumed.

Overdose or a dangerous interaction (such as with certain medications or tyramine-rich foods) may result in Serotonin Syndrome or a Hypertensive Crisis.

When to Seek Emergency Help

Immediate medical attention (call emergency services or go to the nearest emergency room) is mandatory if any of the following severe symptoms occur:

Symptom Category Signs of Severe Toxicity
Cardiovascular/Autonomic Severe high blood pressure (Hypertensive Crisis), irregular or rapid heart rate (tachycardia), profuse sweating, or sustained low blood pressure (hypotension) in a delayed stage.
Neuromuscular Muscle rigidity, severe involuntary muscle contractions (clonus), lack of coordination, or seizures.
Central Nervous System High fever (hyperthermia), confusion, delirium, or loss of consciousness (coma).

It is crucial to inform healthcare providers that the patient has taken an irreversible MAOI like Ирбис, as this requires specialized management and extended monitoring.

Therapeutic Uses of Ирбис

Ирбис is generally applied across domains where symptoms are linked to organ-specific functional stress.

The medication is commonly used to address two primary conditions: the long-term, chronic management of elevated blood pressure (hypertension) and supporting kidney health in patients with Type 2 diabetes who also have high blood pressure.

In both these conditions, Ирбис is considered relevant for managing symptoms related to systemic imbalance. The core benefit is to help ease the symptom burden associated with chronic high blood pressure. This approach is commonly used to help manage the risk of serious long-term complications. For diabetic patients, the treatment may assist with maintaining functional stability in conditions marked by increased physiological stress, while managing manifestations linked to organ-specific functional stress, such as proteinuria.


“By working to stabilize blood pressure, this medication plays a role in managing symptoms that can lead to more serious, long-term health complications.”


Quick Fact: Relief for Sustained Systemic Imbalance

  • The medication supports patients during difficult episodes by easing the impact of symptoms linked to organ-specific functional stress.

Regulatory References

  1. NIH DailyMed overview of Irbesartan

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Ирбис (Irbesartan)

Ирбис (Irbesartan) eligibility is strictly defined by regulatory authorities and is determined by age, pregnancy status, and coexisting medical conditions. The medicine is primarily approved for use only in adults (generally 18 years and older) for essential hypertension, including those with Type 2 diabetes and diabetic nephropathy. Safety and efficacy have not been established for use in children and adolescents.

Absolute Contraindications

Irbesartan is contraindicated and must not be used by specific patient groups. This includes patients with a known hypersensitivity to the active ingredient. Use is strictly prohibited during the second and third trimesters of pregnancy. Additionally, the medicine is contraindicated for patients with diabetes mellitus or moderate to severe renal impairment who are simultaneously taking aliskiren-containing products (a dual RAAS blockade).

Restricted Use and Special Caution

Use is not recommended while breastfeeding or in patients with Primary Aldosteronism. Special caution is also indicated for patients who are volume-depleted or have certain cardiovascular issues, such as aortic or mitral valve stenosis.

What should I know about interactions with other medicines?

The official regulatory profile for Irbesartan is primarily defined by its documented interactions within the Renin-Angiotensin System (RAS) and its effects on serum electrolyte balance.

The most significant restriction is the contraindication of co-administration with Aliskiren in patients diagnosed with diabetes or moderate-to-severe renal impairment (Glomerular Filtration Rate (GFR) less than 60 mL/min/1.73m²). Dual blockade of the RAS, including combination with ACE-inhibitors or other Angiotensin II Receptor Blockers, is generally not recommended due to the documented increase in risks for hyperkalemia, hypotension, and kidney function changes.

Interactions with substances that affect potassium balance are also prominent. Combining Irbesartan with Potassium-Sparing Diuretics, Potassium Supplements, or Potassium-Containing Salt Substitutes increases the documented risk of elevated serum potassium (hyperkalemia).

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or COX-2 Inhibitors may result in attenuation of the blood pressure lowering effect and elevate the risk of worsening renal function, a risk noted to be particularly higher in the elderly or volume-depleted. Other interactions include the risk of increased serum Lithium concentrations leading to toxicity, and Irbesartan's role as a potential OATP1B1 inhibitor, which can increase the exposure of certain co-administered medicines, such as Repaglinide.

Mechanism of Action

Targeted Receptor Modulation

Ирбис works by acting directly on defined receptor systems within key regulatory pathways. It engages mechanisms associated with receptor- or enzyme-mediated signaling, where it either initiates or suppresses the signaling sequences, an action that results in the modulation of specific signaling activity within targeted pathways.


Signal Transduction and Cascade Control

This mechanism modifies the early molecular steps that shape systemic physiological outcomes. By intervening within well-characterized molecular cascades, Ирбис alters the flow and strength of communication in defined neural or humoral pathways. This targeted pathway adjustment is relevant in systems where specific chemical transmitters or mediators dominate. The pathway adjustment influences the propagation of signals associated with excessive activity.


Regulation of System Dynamics

The mechanistic activity produces a change in the steady-state activity of targeted physiological responses. The mechanism influences the dynamics of processes driven by distinct signaling patterns, and Ирбис alters the activity set point within targeted pathways. These resulting physiological adjustments collectively define the observed mechanistic activity.

Dosage and Administration Information

How to Use Ирбис

Ирбис (Irbesartan) is an oral medication administered as a film-coated tablet for long-term therapeutic regimens. The core principle of its use is a once-daily administration schedule, ensuring a consistent level of the active substance in the body. The tablets are designed to be swallowed whole with fluid, and administration can occur with or without food, providing flexibility for the patient.


Standard Dosing and Schedule

The dosage for Irbesartan is standardized and depends on the condition being addressed. The medication is available in strengths including 75 mg, 150 mg, and 300 mg.

Indication Usual Starting Dose Maximum Daily Dose
Hypertension 150 mg once daily 300 mg once daily
Diabetic Nephropathy 75 mg once daily 300 mg once daily

Usage Patterns and Adjustments

Irbesartan is typically used as part of a chronic treatment plan. A patient begins with the starting dose, and subsequent dose adjustments, or titration, should not be considered for at least 2 to 4 weeks after initiation or previous adjustment. This procedural interval allows the current dose to reach its maximal effect before any change is implemented.

In terms of specific patient groups, no initial dose adjustment is generally necessary for most older adults or for individuals with mild-to-moderate renal or hepatic impairment. This defines the standard approach for initiating and maintaining the treatment protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ирбис


Evidence for Use in Managing Essential Hypertension

Research examining patterns related to high blood pressure involves numerous Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms and aimed to assess outcomes related to changes in blood pressure levels. Findings from these studies described patterns observed in the studies related to measured blood pressure levels. The evidence contributes to the broader evidence landscape by providing insight into short-term blood pressure patterns observed when Irbesartan was evaluated alongside both placebo and other anti-hypertensive medicines.

What is still uncertain is that regulatory analysis noted that patterns related to blood pressure measurement were observed to vary across different ethnic groups. Additionally, there is limited information for long-term outcomes concerning hard cardiovascular events (like heart attack or stroke). The follow-up durations were limited in many studies, meaning research focused on short-term symptom patterns.


Evidence for Use in Kidney Disease in Type 2 Diabetes

The most extensive research examining patterns related to kidney disease in patients with Type 2 diabetes who also have high blood pressure was conducted through large-scale, dedicated long-term RCTs. These studies were used in research exploring how symptoms change over time. The studies examined outcomes related to physiological strain or stress, such as the progression to end-stage renal disease and changes in key markers like the doubling of serum creatinine. Findings from these long-term studies, some lasting two years or more, reported patterns in the observed outcomes. The evidence contributes to understanding patterns related to biomarkers, specifically proteinuria and albumin excretion rate, which were key measures in these kidney-focused studies.

Despite the long-term nature of these specific trials, certain areas remain uncertain. There is limited information for long-term outcomes regarding the effect on cardiovascular event rates uniformly across all subgroups. Furthermore, the evidence is limited regarding the use of Irbesartan in patients with advanced chronic kidney disease who do not have concomitant Type 2 diabetes; results apply only to the populations studied.


Research Gaps and What Remains Uncertain

The overall research landscape includes areas where data are limited. Evidence quality varies across studies, particularly regarding certain long-term outcomes. Long-term outcomes are not fully established concerning the durability of blood pressure control over decades. Research gaps noted in regulatory reports include the availability of dedicated comparative evidence for Irbesartan regarding major cardiovascular outcomes relative to other treatments. Data for certain groups remain insufficient, specifically for children under the age of six, and for non-diabetic patients with advanced chronic kidney disease.

Key Studies & References Irbesartan Diabetic Nephropathy Trial (IDNT): Reduction of progression of renal disease in type 2 diabetic patients

Frequently Asked Questions (FAQ)

Common questions about Ирбис (FAQ)

Q: How is Ирбис different from other similar prescription treatments?

Ирбис belongs to a class of medications called Angiotensin II Receptor Blockers (ARBs). Official documentation notes that ARBs work by specifically blocking the AT1 receptor system.

This mechanism is different from other related drugs, like ACE inhibitors, which work by inhibiting an enzyme and affecting a substance called bradykinin.

Q: Are the side effects of Ирбис usually mild or severe?

Side effects are formally categorized by frequency, with many common reactions like dizziness or fatigue reported. Studies indicate that the overall incidence of side effects may be similar to that observed in patients taking a placebo.

However, rare but serious events, such as a severe allergic reaction called angioedema (swelling of the face or throat), have been reported in post-marketing experience.

Q: Are the side effects generally worse when first starting Ирбис?

Regulatory information indicates that certain effects related to low blood pressure, such as dizziness or feeling light-headed, are noted to be more common when beginning treatment or after a dose change.

These feelings are noted to be associated with starting the medication or changing the dose.

Q: What is the most frequently reported side effect of Ирбис according to official sources?

Official product information classifies dizziness and fatigue as common adverse reactions.

For patients with Type 2 diabetes and associated kidney disease, an increase in potassium levels, known as hyperkalemia, is also listed as a frequently reported side effect.

Q: What common foods or drinks are known to interact with Ирбис?

Ирбис can be taken with or without food. However, official safety information highlights a specific interaction concern regarding salt substitutes that contain potassium.

Combining these substitutes with Irbesartan can increase the risk of high potassium levels in the blood, which is an interaction noted in official safety information.

Q: How long does it usually take for Ирбис to start producing its intended effect?

Studies show that the medication begins to produce an observable effect after the first dose. According to the official documentation, the blood pressure-lowering effect is often close to its full potential within approximately two weeks of starting treatment.

Q: Is it important to take Ирбис exactly at the same time every day for it to work properly?

The medication is designed for once-daily dosing to ensure a consistent level of the active substance throughout the day.

Official guidance suggests patients try to take the dose at the same time each day to maintain this consistency.

Q: Can Ирбис be split or crushed if I have difficulty swallowing pills?

The tablets for Ирбис are film-coated and are intended to be swallowed whole with fluid. Official regulatory labeling does not provide instructions for splitting or crushing the tablets.

In situations where swallowing is difficult, regulatory materials recommend consulting a healthcare professional regarding any alterations to the physical form of the medicine.

Q: How common is it to get a skin rash from taking Ирбис?

Official documents list skin rash, or urticaria (hives), as an uncommon adverse reaction.

This means it is reported to occur in less than one in 100 patients. It is also noted as a potential sign of an allergic reaction.

Q: Does Ирбис affect sleep patterns?

According to the official list of side effects, sleep disturbances, including insomnia, are listed in the uncommon category.

This means they are reported to affect less than 1% of patients in studies.

Q: Is weight gain or weight loss a common concern when using Ирбис?

Change in body weight is not commonly listed as a direct side effect in official reports. However, unexpected swelling or rapid weight gain is specifically noted in safety information as it can be a sign of a serious problem, such as worsening kidney function.

Q: Can I take vitamins or herbal supplements while using Ирбис?

Official documents do not provide specific interaction warnings for all generic vitamins or herbal products. However, due to the risk of dangerously elevated potassium levels, the use of potassium supplements and potassium-containing salt substitutes is explicitly cautioned against in regulatory materials.

Q: Does alcohol interact dangerously with Ирбис?

Official patient information notes that alcohol may increase the blood pressure-lowering effect of the medication.

This combination may also increase the likelihood of experiencing certain side effects such as dizziness or lightheadedness.

Q: What general steps should be taken if I forget to take a dose of Ирбис?

Official regulatory guidance describes a procedure for missed doses, indicating that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely.

The guidance explicitly cautions against taking two doses at the same time to compensate for a forgotten one.

Q: Is there a known best time of day to take Ирбис, such as morning or night?

Ирбис is generally prescribed for once-daily use at a consistent time. Due to the potential for the initial dose to cause dizziness, some regulatory advice suggests taking the first dose before bedtime.

After the initial period, the medication can usually be taken at any time of day, provided the schedule remains consistent.

Q: Does İrbis affect the ability to drive or operate machinery?

Official patient information advises caution with activities like driving or operating machinery.

Because common side effects include dizziness or light-headedness, caution is advised for activities requiring alertness until a patient knows how the medicine affects them.

Q: Is it normal to feel a slight change in appetite when starting İrbis?

Regulatory sources list loss of appetite as an infrequently reported side effect.

An increase in thirst or hunger is also mentioned in some documents, as this can be a sign of high blood sugar levels which requires separate monitoring.

How should Ирбис be stored and disposed of?

Official Storage and Disposal Requirements for Irbis (Irbesartan)

Irbis tablets must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is essential to protect the medication from excess heat, moisture, direct light, and freezing. To maintain integrity, the medicine must be kept in the original container and the lid must be tightly closed.

Protection and Disposal

Mandatory safety instructions require that the product be stored out of the sight and reach of children and secured using safety caps. Unused or expired Irbesartan must be disposed of in accordance with local regulations after consulting a healthcare professional. Disposal instructions specifically prohibit releasing the product into wastewater or the sewage system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ирбис found in:

A-Z Index: